Tirzepatide 15mg
Tirzepatide – Dual GIP/GLP-1 Receptor Agonist
Tirzepatide is a synthetically produced peptide that simultaneously activates the receptors of the two naturally occurring incretin hormones GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Through this dual mechanism of action, tirzepatide influences glucose metabolism as well as appetite, satiety, and body weight.
Mechanism of Action
After food intake, GIP and GLP-1 are naturally released in the intestine. Tirzepatide mimics the effects of these hormones and activates their receptors, including those in the pancreas and brain.
As a result, glucose-dependent insulin secretion is increased, while glucagon secretion is reduced. Tirzepatide may also improve insulin sensitivity.
Another important effect involves the regulation of hunger and food intake. Activation of GIP and GLP-1 receptors can increase feelings of fullness and reduce appetite. Tirzepatide also temporarily slows gastric emptying, which can delay nutrient absorption and help reduce post-meal blood glucose spikes.
Potential Benefits
Reduced appetite and food intake
Support for significant weight loss
Improved blood glucose control
Reduction in fasting and post-meal blood glucose levels
Improved glucose-dependent insulin secretion
Reduced glucagon secretion
Improved insulin sensitivity
Support for long-term weight management
In clinical studies, tirzepatide has shown substantial effects on body weight. In a large study involving people with obesity or overweight and at least one weight-related health condition, average weight loss after 72 weeks was approximately 15% or more of initial body weight, depending on the dose studied, compared with around 3% with placebo.
Tirzepatide differs from traditional GLP-1 receptor agonists because it targets two incretin pathways simultaneously: GIP and GLP-1. This combination makes the compound particularly interesting for research into metabolic regulation, glucose homeostasis, obesity, and weight management.
